- Home
- CCIA vs TGTX Comparison
CCIA vs TGTX Comparison
Compare CCIA & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIA
- TGTX
- Stock Information
- Founded
- CCIA N/A
- TGTX 1993
- Country
- CCIA
- TGTX United States
- Employees
- CCIA N/A
- TGTX N/A
- Industry
- CCIA
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CCIA
- TGTX Health Care
- Exchange
- CCIA Nasdaq
- TGTX Nasdaq
- Market Cap
- CCIA N/A
- TGTX 4.2B
- IPO Year
- CCIA 2023
- TGTX 1995
- Fundamental
- Price
- CCIA $25.50
- TGTX $32.22
- Analyst Decision
- CCIA
- TGTX Strong Buy
- Analyst Count
- CCIA 0
- TGTX 5
- Target Price
- CCIA N/A
- TGTX $45.00
- AVG Volume (30 Days)
- CCIA N/A
- TGTX 2.1M
- Earning Date
- CCIA N/A
- TGTX 11-03-2025
- Dividend Yield
- CCIA N/A
- TGTX N/A
- EPS Growth
- CCIA N/A
- TGTX N/A
- EPS
- CCIA N/A
- TGTX 0.36
- Revenue
- CCIA N/A
- TGTX $454,069,000.00
- Revenue This Year
- CCIA N/A
- TGTX $82.58
- Revenue Next Year
- CCIA N/A
- TGTX $44.99
- P/E Ratio
- CCIA N/A
- TGTX $88.81
- Revenue Growth
- CCIA N/A
- TGTX 30.96
- 52 Week Low
- CCIA N/A
- TGTX $21.16
- 52 Week High
- CCIA N/A
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- CCIA 50.23
- TGTX 57.75
- Support Level
- CCIA $25.44
- TGTX $31.29
- Resistance Level
- CCIA $25.49
- TGTX $33.33
- Average True Range (ATR)
- CCIA 0.04
- TGTX 1.13
- MACD
- CCIA 0.01
- TGTX 0.28
- Stochastic Oscillator
- CCIA 71.43
- TGTX 75.48
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.